• About 500 million adults worldwide are suffering from diabetes mellitus
  – with rising tendency.⁽¹⁾
• Roughly one in three patients is affected by diabetic neuropathy.⁽²⁾
• About two thirds of patients with diabetic neuropathy are not aware of their disease.⁽³⁾
• An international board of 15 neuropathy experts developed consensus recommendations and algorithms for screening, diagnosis, and management of diabetic neuropathy in clinical practice.

Diabetic neuropathy is one of the most frequent and severe complications of diabetes mellitus. Although it accounts for considerable morbidity, increased risk of mortality, and reduced quality of life, diabetic neuropathy still remains inadequately diagnosed and treated in practice. For this reason, an international board of 15 neuropathy experts met for a virtual conference on the occasion of the World Diabetes Day 2020 to develop consensus recommendations and algorithms for screening, diagnosis, and management of diabetic neuropathy in clinical practice. These recommendations have been published in September 2021 in the journal “Diabetes Research and Clinical Practice”.⁽⁴⁾

On this website Wörwag Pharma provides information on the current consensus recommendations for health care professionals. Wörwag Pharma is globally committed to prevention, early detection, and therapy of diabetic neuropathy.

Diabetic neuropathy is defined as peripheral nerve dysfunction resulting from diabetes mellitus, after other causes of peripheral neuropathy have been excluded. Damage can occur in the somatic and/or autonomic components of the peripheral nervous system. Diabetic sensorimotor polyneuropathy (DSPN) is the most common form. It affects about 30 percent of diabetes patients and manifests in paresthesias, pain, numbness and/or reduced sensibility (deficits) occurring symmetrically in the feet and legs.